Angaben zur Quelle [Bearbeiten]
| Autor | Davide Cervia, Davide Martini, Chiara Ristori, Elisabetta Catalani, Anna Maria Timperio, Paola Bagnoli, Giovanni Casini |
| Titel | Modulation of the neuronal response to ischaemia by somatostatin analogues in wild-type and knock-out mouse retinas |
| Zeitschrift | Journal of Neurochemistry |
| Ausgabe | 106 |
| Datum | September 2008 |
| Nummer | 5 |
| Seiten | 2224-2235 |
| DOI | 10.1111/j.1471-4159.2008.05556.x |
| URL | http://onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2008.05556.x/pdf |
Literaturverz. |
yes |
| Fußnoten | yes |
| Fragmente | 1 |
| [1.] Clg/Fragment 024 19 - Diskussion Zuletzt bearbeitet: 2014-05-11 16:12:25 Schumann | BauernOpfer, Cervia et al 2008, Clg, Fragment, Gesichtet, SMWFragment, Schutzlevel sysop |
|
|
|
| Untersuchte Arbeit: Seite: 24, Zeilen: 19-24 |
Quelle: Cervia et al 2008 Seite(n): 2224, Zeilen: l.col: 16-20, 24-30 |
|---|---|
| The primary cause of neuronal death in retinal diseases is ischaemia, a condition that can be considered a final common pathway for injury in different retinal pathologies (Quigley et al., 1995; Levin and Louhab 1996). The peptide somatostatin plays important physiological roles, mostly inhibitory, which have formed the basis for the clinical use of SRIF compounds (Weckbecker et al., 2003; Cervia and Bagnoli 2007), and it may protect the retina against ischaemia in a variety of retinal diseases (Cervia et al., 2008).
[...] Cervia D, Martini D, Ristori C, Catalani E, Timperio AM, Bagnoli P, Casini G (2008) Modulation of the neuronal response to ischaemia by somatostatin analogues in wild-type and knock-out mouse retinas. J Neurochem 106(5):2224-35. |
The primary cause of neuronal death in retinal diseases is ischaemia, a condition that can be considered a final common pathway for injury in different retinal pathologies (Quigley et al. 1985, 1995; Levin and Louhab 1996; Osborne et al. 1999, 2004; Barber 2003). [...] The peptide somatostatin (somatotropin release-inhibiting factor, SRIF) plays important physiological roles, mostly inhibitory, which have formed the basis for the clinical use of SRIF compounds (Weckbecker et al. 2003; Cervia and Bagnoli 2007), and it may protect the retina against ischaemia in a variety of retinal diseases (Cervia et al. 2008).
[...] Cervia D., Casini G. and Bagnoli P. (2008) Physiology and pathology of somatostatin in the mammalian retina: a current view. Mol. Cell. Endocrinol. 286, 112–122. |
The source is given in the end for the statement "and it may protect the retina against ischaemia in a variety of retinal diseases". It is not clear to the reader that more is taken from the source including references to the literature. Note that the reference "Cervia et al. 2008" given in the source refers to a different paper than the reference in the dissertation that has been given at the same place. |
|